Strong Generics-led finish to 2023
22/02/24 -"Hikma’s H2 23 results exceeded the street’s expectations, with Generics being the lead performer. Even the 2024 guidance was largely in line with the consensus estimates. The results were cheered by ..."
Pages
53
Language
English
Published on
22/02/24
You may also be interested by these reports :
12/11/26
The Q3 results exceeded consensus estimates, backed by the strong showing of Electronics (driven by demand from AI applications) and healthy support ...
11/11/26
The Q3 profitability materially surpassed expectations, backed by the strong momentum for migraine and depression/schizophrenia treatments. The ...
06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...
06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...